Montserrat Plana
Grupo de investigación
- Sida e infección por VIH Accredited researcher (R3A)
Publicaciones destacadas
-
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Autores:Referencia: Viruses-Basel 2021. -
Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV
Autores:Referencia: Journal Of Controlled Release 2021. -
High rates of long-term progression in HIV-1-positive elite controllers
Autores:Referencia: Journal Of The International Aids Society 2021. -
Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
Autores:Referencia: Scientific Reports 2020. -
Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection
Autores:Referencia: Aids 2020. -
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection
Autores:Referencia: Biochemical Pharmacology 2020. -
A classifier to predict viral control after antiretroviral treatment interruption in chronic HIV-1 infected patients
Autores:Referencia: Jaids-Journal Of Acquired Immune Deficiency Syndromes 2020. -
Local barrier dysfunction identified by confocal laser endomicroscopy predicts bacterial translocation in HIV infection
Autores:Referencia: Aids 2020. -
Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B
Autores:Referencia: Vaccines 2019. -
Therapeutic vaccine in chronically Hiv-1-infected patients: A randomized, double-blind, placebocontrolled phase IIa trial with HTI-Trimix
Autores:Referencia: Vaccines 2019.
Proyectos destacados
-
Red Temática de Investigación Cooperativa en Salud - SIDA (RIS)
Investigador/a principal: Felipe GarcíaFinanciador: Instituto de Salud Carlos IIICódigo: RD16/0025/0002Duración: 01/01/2017 - 31/12/2022 -
Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection (HIVACAR)
Código: CE_H2020-SC1_16abr1sDuración: 02/01/2017 - 31/12/2021 -
FluNanoAir Design of Human Influenza vaccines using multifunctional micelles harnessing innate immunity
Investigador/a principal: Montserrat Plana IP from Partner 2 (FCRB / IDIBAPS)Duración: 01/01/2017 - 31/12/2019 -
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates
Investigador/a principal: Felipe Garcia Alcaide, Giuseppe Pantaleo Co-IPCódigo: CE_H2020-PHCRTD-15Duración: 02/01/2016 - 31/12/2020 -
DESARROLLO DE UNA VACUNA TERAPÉUTICA FRENTE AL VIH BASADA EN UNA NUEVA FORMULACIÓN DE mRNA CON NANOPARTÍCULAS
Duración: 01/01/2016 - 01/01/2018